Cargando…

Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors

Receptor for advanced glycation end-products (RAGE) is a member of the immunoglobulin superfamily. RAGE binds and mediates cellular responses to a range of DAMPs (damage-associated molecular pattern molecules), such as AGEs, HMGB1, and S100/calgranulins, and as an innate immune sensor, can recognize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyeon Jin, Jeong, Mi Suk, Jang, Se Bok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268101/ https://www.ncbi.nlm.nih.gov/pubmed/34199060 http://dx.doi.org/10.3390/ijms22136904

Ejemplares similares

Structure and Activities of the NS1 Influenza Protein and Progress in the Development of Small-Molecule Drugs
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Molecular Characteristics of Amyloid Precursor Protein (APP) and Its Effects in Cancer
por: Lee, Han Na, et al.
Publicado: (2021)

Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors
por: Singh, Harbinder, et al.
Publicado: (2022)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression
por: El-Far, Ali H., et al.
Publicado: (2020)

RAGE Inhibitors in Neurodegenerative Diseases
por: Reddy, V. Prakash, et al.
Publicado: (2023)

RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation
por: Sparvero, Louis J, et al.
Publicado: (2009)

Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges
por: Kamal, Monica A., et al.
Publicado: (2022)

Survivin Small Molecules Inhibitors: Recent Advances and Challenges
por: Albadari, Najah, et al.
Publicado: (2023)

Recent Advances in Small Molecule Inhibitors for the Treatment of Osteoarthritis
por: Lin, Jianjing, et al.
Publicado: (2023)

Virtual screening of RAGE inhibitors using molecular docking
por: Devi Alaparthi, Malini, et al.
Publicado: (2016)

Understand KRAS and the Quest for Anti-Cancer Drugs
por: Han, Chang Woo, et al.
Publicado: (2021)

Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction
por: Manigrasso, Michaele B., et al.
Publicado: (2016)

Structural insights of homotypic interaction domains in the ligand-receptor signal transduction of tumor necrosis factor (TNF)
por: Park, Young-Hoon, et al.
Publicado: (2016)

Structure, signaling and the drug discovery of the Ras oncogene protein
por: Han, Chang Woo, et al.
Publicado: (2017)

Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase
por: Choi, Eungi, et al.
Publicado: (2018)

RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review
por: Faruqui, Tabrez, et al.
Publicado: (2022)

Advances in small molecule inhibitors for treatment of psoriasis
por: Chen, Wen-Juan, et al.
Publicado: (2021)

The Receptor for Advanced Glycation End Products (RAGE) and the Lung
por: Buckley, Stephen T., et al.
Publicado: (2010)

Targeting Tumor Microenvironment by Small-Molecule Inhibitors
por: Zhong, Shangwei, et al.
Publicado: (2019)

Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond
por: Shetu, Shaila A., et al.
Publicado: (2023)

Recent advances in developing small-molecule inhibitors against SARS-CoV-2
por: Xiang, Rong, et al.
Publicado: (2022)

Small Molecule Inhibitors of CXCR4
por: Debnath, Bikash, et al.
Publicado: (2013)

Small molecule inhibitors targeting the cancers
por: Liu, Gui‐Hong, et al.
Publicado: (2022)

Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer
por: Taneja, Sakshi, et al.
Publicado: (2021)

Role of receptor for advanced glycation end products (RAGE) in liver disease
por: Yamagishi, Sho-ichi, et al.
Publicado: (2015)

The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases
por: Delrue, Charlotte, et al.
Publicado: (2023)

Structure and function of vascular endothelial growth factor and its receptor system
por: Park, Seong Ah, et al.
Publicado: (2018)

Advances in Proteasome Enhancement by Small Molecules
por: George, Dare E., et al.
Publicado: (2021)

Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases
por: Lee, Eun Ji, et al.
Publicado: (2013)

CD38, CD157, and RAGE as Molecular Determinants for Social Behavior
por: Higashida, Haruhiro, et al.
Publicado: (2019)

COVID-19 rhapsody: Rage towards advanced diagnostics and therapeutic strategy
por: Sinha, Koel, et al.
Publicado: (2021)

The Remarkable Roles of the Receptor for Advanced Glycation End Products (RAGE) and Its Soluble Isoforms in COVID-19: The Importance of RAGE Pathway in the Lung Injuries
por: Salehi, Mitra, et al.
Publicado: (2022)

Receptor for the Advanced Glycation End Products (RAGE) Pathway in Adipose Tissue Metabolism
por: Gutowska, Klaudia, et al.
Publicado: (2023)

Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis
por: Wu, Rui, et al.
Publicado: (2020)

Small Molecules—Prospective Novel HCMV Inhibitors
por: Bogner, Elke, et al.
Publicado: (2021)

Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
por: Li, Shasha, et al.
Publicado: (2021)

Small Molecule Inhibitors of Influenza Virus Entry
por: Chen, Zhaoyu, et al.
Publicado: (2021)

Polymorphisms −374 T/A and −429 T/C of the Receptor for Advanced Glycation End-Products (RAGE) and Serum Levels of RAGE (sRAGE) Are Not Associated with Metabolic Syndrome
por: González-Guerrero, Diana Elizabeth, et al.
Publicado: (2023)

RAGE in the pathophysiology of skeletal muscle
por: Riuzzi, Francesca, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ntofpvuvknmv1sng3c42fip68t